Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204164 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
A Phase 1 study, sponsored by Tragara Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT01204164: Completed Phase 1 study, sponsored by Tragara Pharmaceuticals.
NCT01204164 is a Phase 1 study that has completed, run by Tragara Pharmaceuticals. The registered enrollment target is 120 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204164, a Phase 1 study, has completed, sponsored by Tragara Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose escalation Phase 1 study.
Primary Outcome
Maximum Tolerated Dose refers to the highest dose of TG02 administered that will produce the desired effect without unacceptable toxicity.
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG TG02 citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT01204164 record still lists
NCT01204164 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (100% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01204164 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01204164 about?
NCT01204164 is a clinical study titled "Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies". This is a multicenter, open-label, dose escalation Phase 1 study.
What is the current status of trial NCT01204164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2010-08. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01204164?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), TG02 citrate (DRUG).
Who is sponsoring clinical trial NCT01204164?
This trial is sponsored by Tragara Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01204164's enrollment target sits among peer trials
120 479th of 2000 higher than 1,503 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia